A Clinical Phase I/II, Multicenter, Open-label, National Study Evaluating Quintuplet Treat-ment With ISaTuximab, Bortezomib, Lenalidomide and Dexamethasone Plus Etentamig (Etenta-Isa-VRd) in Primary DiagnOsed High-Risk Multiple Myeloma Patients

This study is researching an experimental five-drug combination called etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) and high-risk disease who are eligible for autologous stem cell transplantation.

Start Date01 Dec 2026

Sponsor / Collaborator

Universitätsklinikum Hamburg-Eppendorf

[+2]

NCT07728188

/ Not yet recruitingPhase 3

A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.
Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide.
Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date30 Nov 2026

Sponsor / Collaborator

AbbVie, Inc.

NCT07793422

/ Not yet recruitingPhase 3

A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Amyloid light chain (AL) amyloidosis is a rare disease caused by abnormal plasma cells producing misfolded light chain proteins that deposit in organs, leading to organ dysfunction and failure. The goal of this study is to evaluate the safety and efficacy of etentamig compared to daratumumab plus cyclophosphamide plus bortezomib plus dexamethasone (Dara-CyBorD) in participants with newly diagnosed AL amyloidosis.
Etentamig is an investigational drug being developed for the treatment of newly diagnosed AL amyloidosis. This is an open-label study. The study consists of 2 parts: a Safety Run-in where participatns will receive etentamig, and a Randomized Portion with 2 treatment arms where participants will receive etentamig, or Dara-CyBorD. Approximately 370 participants will be enrolled in the study at approximately 130 sites worldwide.
Participants will receive injected etentamig, in the Safety Run-in. Participants will receive injected etentamig, or Dara-CyBorD per the local label, in the Randomized Portion of the study. The total study duration is approximately 96 months.
There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Start Date29 Nov 2026

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Etentamig

100 Translational Medicine associated with Etentamig

100 Patents (Medical) associated with Etentamig

Literatures (Medical) associated with Etentamig

03 Dec 2025·Cureus Journal of Medical Science

Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Review

Author: Jawed, Inshal ; Khan, Asad Ali ; Sajjad, Muhammad ; Rahman, Mansoor ; Khan, Muhammad Musa

Relapsed/refractory multiple myeloma (RRMM) remains a challenging condition with a need for more effective treatment options. There are ongoing clinical trials analyzing the effects of anti-B-cell maturation antigen (BCMA) bispecific antibodies (Abs) against RRMM with early, promising results. This study aims to systematically evaluate the safety and efficacy of anti-BCMA bispecific antibodies in patients with RRMM. PubMed, Embase, Web of Science, and the American Society of Hematology (ASH) website were searched for published evidence on the safety and efficacy of anti-BCMA bispecific Abs. Screening was performed using original clinical trials published in English, RRMM, and anti-BCMA-CD3 bispecific Abs as our inclusion criteria. Our search yielded a total of 2211 articles. After screening, we found 11 relevant clinical trials (five phase I, one phase I/II, two phase Ib, two phase II, one phase III). Across the trials, 910 patients with ages ranging from 32 to 82 years were analyzed. A majority of patients were exposed to and/or refractory to triple-class and penta-drugs (prior therapies ranged from 1 to 25). AMG-420, AMG-701, elranatamab, REGN5458, teclistamab (Tec), alnuctamab (ALNUC), and ABBV-383 are the seven anti-BCMA-CD3 bispecific Abs currently being assessed in clinical trials as monotherapy and in combination with immunomodulators/proteasome inhibitors against RRMM. Across the included trials, elranatamab demonstrated overall response rates (ORRs) of 61-64%, while teclistamab ranged from 40% to 78% depending on the regimen. ALNUC and ABBV-383 achieved ORRs of 51% and 57%, respectively. Among patients previously exposed to and/or refractory to anti-BCMA therapies (including antibody-drug conjugates and CAR-T cell therapy), ORRs were 54% for elranatamab and 40% for teclistamab. Incidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) was low with subcutaneous (SC) administration of tec, elranatamab, and ALNUC. Across the studies, no death was reported due to CRS, although it led to treatment discontinuation in one patient in AMG-420, two patients in AMG-701, and dose reduction in three patients in ABBV-383 trials. Our analysis of the trials revealed that bispecific Abs showed efficacy in RRMM, with CRS and hematologic toxicities being the most common adverse events, mostly low-grade and manageable. Based on the promising efficacy and safety of BCMA targeting bispecific Abs, these drugs are emerging as a new therapeutic option for patients with advanced and RRMM.

01 May 2025·Clinical Lymphoma Myeloma & Leukemia

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives

Review

Author: Rasche, Leo ; Waldschmidt, Johannes M ; Einsele, Hermann ; Kortüm, K Martin

Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of "off-the-shelf" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Meanwhile, the range of available bsAbs is rapidly expanding, offering patients and healthcare providers a broad selection of options that vary in target antigens, binding domains, construct designs, dosing regimens, and side effects. As linvoseltamab, alnuctamab, and ABBV-383 (all BCMA × CD3), as well as forimtamig (GPRC5D × CD3) and cevostamab (FcRH5 × CD3) progress through late-stage clinical development, emerging trispecific antibodies are now available that target either 2 different MM-associated antigens or provide additional co-stimulatory signals to prevent T-cell exhaustion. Despite this plethora of therapeutic options, resistance to bsAbs is an inevitability, and the optimal positioning of these drugs within the current MM treatment landscape remains to be determined. In this review, we examine the available data on all clinically accessible bsAbs, evaluating their potential, current limitations, and implications for efficacy and safety, with the aim of achieving deeper responses and longer overall survival for MM patients.

02 Nov 2022·Cancer discovery

ABBV-383 Demonstrates Tolerability and Efficacy in Relapsed/Refractory MM

Article

Abstract:

The T cell–engaging bispecific antibody ABBV-383 was well tolerated in relapsed/refractory multiple myeloma (RRMM).

News (Medical) associated with Etentamig

17 Sep 2026

·www.biospace.com

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill. , Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23 rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings. Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma. "Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options." The full list of AbbVie presentations at IMS includes: Note: All presentation times are listed in local Glasgow time. Abstract Title Date/Time Session Abstract Number Real-World (RW) Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) in Europe: Results from the HARMONY Big Data Platform Wednesday, September 23, 2026 12:00–1:00 PM Poster Presentation PA-386 Etentamig in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B- Cell Maturation Antigen (BCMA)-Targeted Therapy Thursday, September 24, 2026 12:00–1:00 PM Poster Presentation PA-181 A Phase 1/2, Open-Label, Platform Study to Evaluate the Safety and Efficacy of Etentamig Monotherapy or Combination Therapy in Patients with Multiple Myeloma Friday, September 25, 2026 12:00–1:00 PM Poster Presentation PA-008 Phase 1/2, Open-Label, Platform Study of Surzetoclax with Etentamig in Biomarker- Selected Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Friday, September 25, 2026 12:00–1:00 PM Poster Presentation PA-346 Real-World (RW) Infection-Related Healthcare Resource Utilization (HCRU) and Costs in Patients (pts) with Multiple Myeloma (MM) Receiving T-cell Redirecting Therapies (TCRTs) Friday, September 25, 2026 12:00–1:00 PM Poster Presentation PA-387 CERVINO: Phase (Ph) 3 Results of Etentamig vs Investigator's Choice of Standard Available Therapies (SAT) in Patients (Pts) With Triple- Class Exposed Relapsed or Refractory Multiple Myeloma (RRMM) Friday, September 25, 2026 3:00–5:00 PM Plenary Session Hall 5 LBA-01 Etentamig Combined With Pomalidomide Plus Dexamethasone (Pom+Dex) in Relapsed/ Refractory Multiple Myeloma (RRMM) After 1–3 Prior Lines of Therapy: A Phase 1b Dose- Escalation and Safety Expansion Study Saturday, September 26, 2026 8:30–9:30 AM Oral Presentation Abstract Session 9 Hall 5 OA-24 AbbVie Advances ABBV- 2001/ISB 2001: A Unique, Single-Molecule Trispecific T-cell Engager (TCE) Approach Toward Robust Anti-Myeloma Activity with Superior Tumor Cytotoxicity Saturday, September 26, 2026 9:30–10:20 AM Oral Presentation Future Targets and New Modalities of Therapy Hall 5 N/A Surzetoclax: A Potentially Best-in-Class BCL-2 Inhibitor for the Treatment of Multiple Myeloma with t(11;14) Translocation or High BCL-2 Expression N/A Poster Presentation PA-468 More information about the IMS 2026 meeting, including AbbVie's presence, will be available here . Additional information around AbbVie's ongoing clinical trials in multiple myeloma can be found at clinicaltrials.gov . Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook , Instagram , X and YouTube. About AbbVie in Oncology  AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.  Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit  .  Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Media: Sourojit (Jit) Bhowmick, Ph.D. Jit.Bhowmick@abbvie.com Investors: Liz Shea Liz.Shea@abbvie.com View original content: SOURCE AbbVie

04 Sep 2026

·www.biopharmadive.com

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

Dive Brief:AbbVie said its dual-acting drug for multiple myeloma met the main goal of a Phase 3 clinical trial, helping people whove progressed on two or more lines of therapy survive longer without progression than those who received standard treatment regimens, the company said Thursday.The drug, called etentamig, could be safer than rival drugs launched by Johnson & Johnson, Pfizer and Regeneron, with low rates of two kinds of serious immune responses common to other drugs of its type. AbbVie said its safety profile could enable greater use in community oncology centers because of reduced need for post-treatment patient monitoring.Etentamig is a type of drug called a bispecific antibody that can simultaneously bind to diseased tumor cells and T cells, triggering an immune response to fight multiple myeloma. It trails by more than four years the first drug in its class, J&Js Tecvayli, which booked $462 million in sales through the first six months of 2026.Dive Insight:Immunotherapy has reshaped care across nearly every type of cancer, and the blood cancers like leukemia, lymphoma and multiple myeloma have been part of that transformation. In blood cancers, it first started with a type of engineered cell treatment called CAR-T therapy, and dual-acting bispecific antibodies have followed closely behind.Bispecific antibodies have an advantage against CAR-T therapies, which require extensive re-engineering of patients own cells to fight cancer. But they still carry some of the same safety issues, specifically immune responses called cytokine release syndrome and a neurological condition called ICANS, which have required similar post-treatment monitoring protocols that patients who receive CAR-T therapies have to undergo.Oncologists have been refining those monitoring protocols to enable more patients to bypass inpatient stays, such as giving them their own tools to monitor symptoms as well as preventive treatments. A drug with reduced side effects could have an edge, however.AbbVies trial enrolled 421 people with multiple myeloma, and randomized half to get etentamig. Independent trial monitors detected a significant difference between the two groups at a pre-planned interim checkpoint, prompting investigators to unblind the trial, leaving 393 people evaluable at an average of 11 months after trial entry.On efficacy,etentamig reduced the risk of progression or death by 60% compared with standard therapies, and stimulated a response in 74% of the enrollees who got it, significantly more than the 46% of those on standard therapies who responded, AbbVie said.On safety, 28% got CRS in the etentamig group, and only one got ICANS. By comparison, in clinical trials nearly three-quarters of Tecvayli patients got CRS, along with more than half of people who received Pfizers Elrexfio and 46% of those who got Regenerons Lynozyfic.Most participants in AbbVies trial who developed CRS also only experienced a mild form of the immune response.The profile gives etentamig the potential to provide access across a range of treatment settings beyond specialized treatment centers and into outpatient and community-based settings, said Peter Voorhees, a trial investigator and chief of the plasma cell disorders division at Atrium Health Levine Cancer Institute, in a statement provided by AbbVie.AbbVie said it will discuss the trial results with regulators and present the data later this month at the International Myeloma Society Annual Meeting. '

Clinical ResultImmunotherapyPhase 3Cell TherapyASCO

04 Sep 2026

·www.biospace.com

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

beast01/Getty Images AbbVie’s etentamig has a relatively cleaner safety pro an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BMO Capital Markets. AbbVie’s investigational anti-BCMA bispecific T cell engager significantly cut the risk of disease progression or death in a late-stage multiple myeloma study. In the Phase 3 CERVINO trial, AbbVie’s asset, dubbed etentamig, showed a 60% progression-free survival (PFS) benefit versus standard available therapies, according to a news release on Thursday . The study enrolled 421 patients with relapsed or refractory multiple myeloma (RRMM) who had undergone at least two prior lines of therapy. Aside from PFS, etentamig also hit CERVINO’s other primary endpoint of objective response rate. A monthly course of etentamig elicited treatment response in 74% of patients, as opposed to 45.7% in the control arm. The CERVINO readout was presented at the 23rd International Myeloma Society Annual Meeting in Scotland. These findings point to the “clear efficacy” of etentamig in RRMM patients, BMO Capital Markets wrote to investors on Thursday. But what could set AbbVie’s asset apart in the market, the analysts continued, is its “potentially differentiated administration profile.” Etentamig makes use of a single step-up dose, after which the drug can be given once every four weeks. Meanwhile, Johnson & Johnson’s Tecvayli —a similar BCMA-targeting bispecific T cell engager that won its first multiple myeloma nod in 2022—requires two step-up doses before transitioning to a weekly then biweekly schedule. Patients only graduate to monthly frequency after 25 weeks. A more recent competitor, Regeneron’s Lynozyfic , similarly requires two step-up doses and requires weekly and biweekly injections before patients transition to a monthly schedule. Lynozyfic was approved in July 2025 and is also a bispecific T cell engager that targets BCMA. Safety also appears to be an edge for etentamig, BMO said. AbbVie reported a 28.3% rate of cytokine release syndrome, which the analysts called “relatively low.” Most of these episodes were grade 1, with no case reaching grade 3 or above. There was only one patient who developed immune effector cell-associated neurotoxicity syndrome (ICANS), which was rated grade 1, AbbVie said. “Collectively, the data position etentamig as a potentially attractive BCMA option that could expand use beyond large academic centers and into community settings,” BMO noted. AbbVie plans to bring CERVINO’s data to global regulatory authorities to determine a path forward for etentamig, though the pharma hasn’t yet provided a specific timeline for a submission. Cancer 5 Therapies Moving the Multiple Myeloma Space Forward A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told BioSpace . Here are five therapies that could change the treatment paradigm. March 9, 2026 · 8 min read · Tristan Manalac Read more

100 Deals associated with Etentamig

External Link

KEGG	Wiki	ATC	Drug Bank
D12990	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	Phase 3	United States	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Australia	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Canada	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	France	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Germany	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Hungary	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Italy	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Netherlands	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Norway	AbbVie, Inc.	30 Nov 2026
Refractory Multiple Myeloma	Phase 3	Portugal	AbbVie, Inc.	30 Nov 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06158841 (CERVINO, PRNewswire) Manual	Phase 3	Relapse multiple myeloma	393	Etentamig	wdjzskewqi(kyujcrjgxh) = nvtaftxyyg ntdgffpkks (fnjdeilikx, 67.25 - 79.97) Met View more	Positive	03 Sep 2026
NCT06158854 (M24-209, EHA2026)	Phase 1	Immunoglobulin Light-Chain Amyloidosis	34	Etentamig	keayttsqbb(zssitkiwhd) = dxebzpnmqa ricfzquwns (algaqsecqq ) View more	Positive	12 May 2026
NCT05259839 (ASH2025) Manual	Phase 1	Multiple Myeloma Third line	85	Etentamig + POM+DEX	phgpaleucp(eaoywpjsfx) = were neutropenia (78%), anemia (28%), and thrombocytopenia (22%). dwdyjmdsdw (gfxmenzras ) View more	Positive	06 Dec 2025
NCT05650632 (ASH2025)	Phase 1	Relapse multiple myeloma	33	Etentamig (Relapsed/Refractory Multiple Myeloma)	qnpwxwirrl(iajfmasvhh) = no recurrent CRS events were observed beyond Cycle 1 xnotacqwrl (pztqsveqbn ) View more	Positive	06 Dec 2025
NCT03933735 (M22-466, ASH2025)	Phase 1	Refractory Multiple Myeloma	20	Etentamig	nskbczufuf(qzdvtvzwqo) = dreabdzvzm liczcnndka (akquelhftu, 0.2)	Positive	06 Dec 2025
NCT03933735 (M22-466, ASH2025)	Phase 1	Refractory Multiple Myeloma	20	Etentamig (MRD-negative (<10-5))	nskbczufuf(qzdvtvzwqo) = dilisjfbfx liczcnndka (akquelhftu, 0.2)	Positive	06 Dec 2025
NCT06158854 (M24109, ASH2025)	Phase 1/2	Immunoglobulin Light-Chain Amyloidosis	12	Etentamig	axjgacnuxz(gjlrgfkidz) = dmmdbtyaox lvyoqaibsw (hlesuozfiw ) View more	Positive	06 Dec 2025
NCT03933735 (IMS2025)	Phase 1	Relapse multiple myeloma Last line	146	Etentamig 60 mg Q4W	ibnsljuhwj(nxdbxctxcl) = ovzskwxdav ortwovwkgr (rjgnppjkck ) View more	Positive	17 Sep 2025
NCT03933735 (Ph 1 studies, ASCO2025)	Phase 1	Relapse multiple myeloma BCMA \| CD3	146	Etentamig 60 mg Q4W	dookmmeony(txqpflejtl) = CRS incidence was 30% (4% G2; No ≥G3 events) with median time to CRS onset of 22.3 (5.5-29.6) hours; and median time to CRS resolution of 20.7 (1.8-131.7) hours zpjbnwllxo (tqcdcjvrjo ) View more	Positive	30 May 2025
NCT05650632 \| NCT03933735 (EHA2025)	Phase 1	Relapse multiple myeloma BCMA \| CD3	146	Etentamig 60 mg Q4W	ymfgvjmeyy(hjocxtnmwy) = iljtkhchwc kraoowoziz (ceajezvinr ) View more	Positive	14 May 2025
NCT05650632 \| NCT03933735 (PF764, EHA2025)	Phase 1	Relapse multiple myeloma	146	Etentamig (Non-Black patients)	mtyajhfift(qqcookykuj) = djgbweeats etjqohfaqb (gromplnbnm, 21% grade 1 and 5% grade 2) View more	Positive	14 May 2025
NCT05650632 \| NCT03933735 (PF764, EHA2025)	Phase 1	Relapse multiple myeloma	146	Etentamig (Black patients)	mtyajhfift(qqcookykuj) = vxxanipjbb etjqohfaqb (gromplnbnm, all grade 1) View more	Positive	14 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis